Open AccessThe Evolution of Oral Contraceptives: Maximizing Efficacy, Minimizing Risks
Author(s) -
Hedon Bernard
Publication year - 1990
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349009156500
Subject(s) - medicine , progestin , stroke (engine) , estrogen , myocardial infarction , family planning , disease , embolism , birth control , incidence (geometry) , intensive care medicine , gynecology , population , research methodology , environmental health , mechanical engineering , physics , optics , engineering
No single pharmacologic agent has been more widely studied than the oral contraceptive (OC). Scientific efforts have been directed primarily toward maximizing the benefits of OCs—which remain the most effective, reversible form of birth control—while minimizing their potential risks, specifically thromboembolic disorders and cardiovascular disease. Decreases in the dose of estrogen from the 100 μg—150 μg levels of the 1960s to the 30 μg—50 μg formulations of today have been accompanied by dramatic reductions in the risk of thromboembolic events. In healthy women not predisposed to these conditions, the risk of thromboembolism is now considered very small. Similar reductions in the doses of progestin have also resulted in decreases in the incidence of stroke and myocardial infarction. Evidence suggests that not only dose but androgenic activity of a progestin may negatively impact on risk of cardiovascular disease. Thus development of OCs containing a progestin with the least potential for androgenically mediated side effects appears to be advisable.